Reduced‐Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series
Authors' conclusion
In patients with prior weight loss and metabolic improvement on GLP1 therapy, reduced-frequency maintenance dosing preserved outcomes. These findings support structured de-escalation as a promising strategy to reduce treatment burden without sacrificing efficacy.
Study context
- Population
- Adults who achieved weight plateau on weekly semaglutide or tirzepatide
- Participants
- 30 adults
- Exposure
- Reduced-frequency vs weekly GLP-1 RA dosing
- Outcome
- Change in body weight from plateau to maintenance
Main finding
As reported in the abstract
Body weight
P < 0.01
Observational data: associations, not effects.
Secondary outcomes
Body composition
- Total body and truncal fat declined, while skeletal muscle mass stabilized on reduced-frequency regimen
Metabolic parameters
- Improved during weekly dosing; gains maintained during reduced-frequency therapy
Original publication
Reduced‐Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity (Silver Spring). Published 24 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →